Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of April 2026, specifically dated April 28, 2026. The report details the vesting of a conditional share award under the GSK 2017 Performance Share Plan (PSP) granted to the Chief Financial Officer, Julie Brown, on April 27, 2023.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It focuses exclusively on executive compensation details:
- Transaction Type: Vesting of 2023 Performance Share Plan award.
- Shares Vested: 243,880 Ordinary Shares (including accrued dividends).
- Transaction Price: £0.00 (non-cash vesting event).
- Market Price: The closing price of GSK Ordinary Shares on the vesting date (April 27, 2026) was £20.16.
- Vesting Outcome: 82% of the award vested; 18% lapsed.
Material Changes
This filing reports a specific corporate action rather than a period-over-period financial change. The material event is the finalization of the CFO's 2023 PSP award following the third anniversary of the grant. The vesting percentage (82%) aligns with the broader 2023 PSP awards that vested on February 13, 2026.
Outlook, Risks, and Unusual Items
Management Commentary and Conditions: The vested shares are subject to an additional two-year holding period for the CFO. The performance measure outcomes and vesting levels are consistent with the announcement made on February 17, 2026. No forward-looking guidance, risk factors, or unusual items regarding the company's operations are disclosed in this specific filing.
Investor Verification Checklist
- Verify the total number of shares vested (243,880) against the initial grant size to confirm the 82% vesting rate.
- Confirm the two-year holding period restriction applies to the vested shares for the CFO.
- Review the February 17, 2026 announcement referenced in the text for detailed performance measure outcomes.
- Note that this filing contains no financial performance data for GSK plc for the period ending April 2026.